TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04206488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: Participants will receive JNJ-70033093 orally.
Study: NCT00634348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
Study: NCT04206488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive digoxin orally.
Study: NCT00650767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-438162, MEK inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-438162, MEK inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-438162, MEK inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT03893032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Description: single 200 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed amphetamine salts
Description: single 10 mg dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral-administration placebo tablet
Study: NCT03692702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE PLAY
Description: WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
Study: NCT01593553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG screening for atrial fibrillation using intermittent ECG recorder
Description: ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
Study: NCT02951143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
Study: NCT03661814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
Study: NCT02951143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
Study: NCT00625079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil
Description: the dose of sildenafil will be 20mg three times per day (orally)
Study: NCT01940120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair using MitraClip implant
Description: Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
Study: NCT01285648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cpap
Description: This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cpap
Description: This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
Study: NCT04490434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg, bid
Study: NCT01628939

Intervention type: OTHER
Intervention: MRI of the lumbar spine
Description: standard protocol, approximately 30 minutes

Intervention type: OTHER
Intervention: MRI of the lumbar spine
Description: standard protocol, approximately 30 minutes

Intervention type: OTHER
Intervention: manual segmental examination of the lumbar facet joints
Description: use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1

Intervention type: OTHER
Intervention: manual segmental examination of the lumbar facet joints
Description: use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
Study: NCT01417923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: P.O.4000 units Vit D per day for 6 weeks
Study: NCT03587272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab, low dose total body irradiation, Sirolimus
Description: The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year.
Study: NCT01614899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496 40mg
Description: once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496 80mg
Description: once daily orally
Study: NCT04490434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 15mg, qd
Study: NCT00204542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Solaraze® (Diclofenac sodium) 2x/day topical for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
Study: NCT01361308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brisdelle (paroxetine mesylate)
Description: Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
Study: NCT03962751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Post Feedback Intervention Delivery
Description: Simultaneous PFI delivery after baseline survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Post Feedback Intervention Delivery
Description: Simultaneous PFI delivery after baseline survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential Post Feedback Intervention Delivery
Description: Sequential PFI delivery over 3 weeks after baseline survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential Post Feedback Intervention Delivery
Description: Sequential PFI delivery over 3 weeks after baseline survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Boosters
Description: Text message boosters on PFI content during week of high risk drinking event
Study: NCT04490434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 15mg, qd
Study: NCT01720459

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized trans-resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05687240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi
Description: Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
Study: NCT03962751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Boosters
Description: Text message boosters on PFI content during week of high risk drinking event
Study: NCT04037540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operational approach
Description: Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative approach
Description: Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
Study: NCT00453336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
Study: NCT00625079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: the dose of sildenafil will be 20mg three times per day (orally)
Study: NCT03871699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Administration of Ferric Carboxymaltose intravenously, one dose only.
Study: NCT03967054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
Study: NCT01614899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily orally
Study: NCT06207747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: additional PET/CT at 4 weeks, analysing using quantative analysis
Description: Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
Study: NCT04014686

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No exercise intervention group
Description: no exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance band exercise intervention group
Description: Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
Study: NCT04156685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, Reference (D635 10/500mg, Astrazeneca)
Description: Once a day. Under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, Reference (D635 10/500mg, Astrazeneca)
Description: Once a day. Under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B, Reference (D635 10/500mg, Astrazeneca)
Description: Once a day. Under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B, Reference (D635 10/500mg, Astrazeneca)
Description: Once a day. Under fed condition
Study: NCT03152409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325mg
Description: Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
Study: NCT02465632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02161432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: single dose BI 187004 given as tablet in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: single dose BI 187004 given as tablet in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: single dose BI 187004 given as oral solution
Study: NCT01918943

Intervention type: DEVICE
Intervention: PLIF and Aspen (spinous process fixation device)
Description: Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
Study: NCT02217098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GIC Restorations
Description: Restorations using Glass Ionomer Cement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbomer Restorations
Description: Restorations using Glass Carbomer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compomer Restorations
Description: Restorations using Compomer
Study: NCT03771573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
Study: NCT03116958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Standard care
Description: CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP + Telemedicine
Description: CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
Study: NCT03967054

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo in the same size, color and shape at the ivermectin tablet
Study: NCT04852939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's technique
Description: Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: * Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks.
Study: NCT01797458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Restorative Caries Treatment
Description: Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Restoration
Description: Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration
Study: NCT04245982

Intervention type: PROCEDURE
Intervention: Gingival biopsy
Description: Two gingival biopsies from each participant were collected.

Intervention type: PROCEDURE
Intervention: Gingival biopsy
Description: Two gingival biopsies from each participant were collected.

Intervention type: PROCEDURE
Intervention: Gingival biopsy
Description: Two gingival biopsies from each participant were collected.
Study: NCT05814380

Intervention type: RADIATION
Intervention: 99mTc-DPD scintigraphy
Description: 99mTc-DPD scintigraphy

Intervention type: RADIATION
Intervention: 99mTc-DPD scintigraphy
Description: 99mTc-DPD scintigraphy

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood samples and echocardiography
Description: Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
Study: NCT03771573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: monitoring
Description: the patients will be under monitoring to investigate the evolution of the disease
Study: NCT03567356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAT-PLUS Helping Hands
Description: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing.
Study: NCT05814380

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood samples and echocardiography
Description: Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
Study: NCT03653780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso GT
Description: Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
Study: NCT04213001

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasonographic measurement
Description: ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
Study: NCT00709449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxaverine
Description: intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxaverine
Description: intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxaverine
Description: intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
Study: NCT03218657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole hydrochloride
Description: levamisole hydrochloride take orally 150mg qod

Intervention type: DRUG
Group type: OTHER
Intervention: Androgens
Description: Androgens take orally 80mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgens
Description: Androgens take orally 80mg qd

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporins
Description: Cyclosporines take orally 3-5mg/kg\*d qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: Cyclosporines take orally 3-5mg/kg\*d qd